Promising results from Oxford AstraZeneca trials

Extremely encouraging new data has just been released in regards to the efficacy (effectiveness) of the Astra Zeneca Oxford Vaccine. The calculations of Vaccine efficacy comes from data from 17,177 participants in trials across the globe. These trials took place in the UK, South Africa and Brazil. The most exciting news surrounds the effectiveness ofContinue reading “Promising results from Oxford AstraZeneca trials”

Unfair criticism of Oxford AstraZeneca Vaccine?

The AstraZeneca Oxford vaccine has in my view unfairly come in for a lot of stick of late. It has the potential to be the game changing vaccine globally. A single £2.25 dose has demonstrated a 76% efficacy in global trials (with no severe cases of COVID that required hospital treatment amongst the 10,000 individualsContinue reading “Unfair criticism of Oxford AstraZeneca Vaccine?”

“What can we learn from Oxford University (B.1.1.7) study in regards to the likely efficacy of COVID vaccines against new and emerging variants”

Oxford analysed the neutralising antibody activity towards the B.1.1.7 UK variant of the virus. They used the blood of people vaccinated with their vaccine to compare the response of these neutralising antibodies against the UK B.1.1.7 variant and a virus called “Victoria”. Victoria is a variant of the virus that is near identical to theContinue reading ““What can we learn from Oxford University (B.1.1.7) study in regards to the likely efficacy of COVID vaccines against new and emerging variants””

What can hospital admission data tell us about transmission of COVID in Early years settings

There was an increase in the number of young people being admitted to hospital with COVID in the two months prior to Christmas. In January there was a significant decline in hospitlisations amongst 6-17 year olds but this was not seen amongst 0-5 year olds. Why might this be the case? Nurseries have remained openContinue reading “What can hospital admission data tell us about transmission of COVID in Early years settings”

Should the UK public be alarmed by the news that the Oxford AstraZeneca vaccine does not offer protection against mild/moderate COVID infections caused by the B.1.352 South Africa variant?

Oxford have reported that their vaccine offers minimal protection against mild/moderate COVID infection caused by the South African variant of the virus B.1.351 🇿🇦. However importantly the vaccine may still protect individuals from severe disease/hospitalisation. There were no cases of Severe disease/hospitalisations in either the vaccinated or the placebo group which is why Oxford are unableContinue reading “Should the UK public be alarmed by the news that the Oxford AstraZeneca vaccine does not offer protection against mild/moderate COVID infections caused by the B.1.352 South Africa variant?”

Create your website with WordPress.com
Get started